Match!
Mahmood Ayub
University of Manchester
27Publications
5H-index
398Citations
Publications 27
Newest
#1Sumitra Mohan (University of Manchester)
#2Mahmood Ayub (University of Manchester)H-Index: 5
Last.Gerard Brady (University of Manchester)H-Index: 22
view all 0 authors...
Serial biopsy of pancreatic ductal adenocarcinoma (PDAC), to chart tumour evolution presents a significant challenge. We examined the utility of circulating free DNA (cfDNA) as a minimally invasive approach across a cohort of 55 treatment-naive patients with PDAC; 31 with metastatic and 24 with locally advanced disease. Somatic mutations in cfDNA were detected using next generation sequencing in 15/24 (62.5%) and 27/31 (87%) of patients with locally advanced and metastatic disease, respectively....
#1Sumitra Mohan (University of Manchester)
#2Victoria Foy (University of Manchester)H-Index: 3
Last.Gerard Brady (University of Manchester)H-Index: 22
view all 0 authors...
Abstract Introduction Small cell lung cancer (SCLC) accounts for ∼250,000 deaths worldwide each year. Acquisition of adequate tumour biopsies is challenging and liquid biopsies present an alternative option for patient stratification and response monitoring. Methods We applied whole genome next-generation sequencing (NGS) to circulating-free DNA (cfDNA) from 39 patients with limited-stage (LS-SCLC) and 30 of patients with extensive-stage (ES-SCLC) to establish genome wide copy number aberrations...
#1Chang Sik Kim (University of Manchester)H-Index: 1
#2Sumitra Mohan (University of Manchester)H-Index: 7
Last.Crispin J. Miller (University of Manchester)H-Index: 35
view all 7 authors...
#1Dominic G. RothwellH-Index: 21
#2Mahmood AyubH-Index: 5
Last.Matthew Krebs (University of Manchester)H-Index: 14
view all 42 authors...
Sequencing of circulating tumor DNA from cancer patients is a cost-efficient approach with turnaround time compatible with clinical practice to inform treatment decision-making in a phase 1 trial setting
#1Sumitra MohanH-Index: 7
#2Victoria FoyH-Index: 3
Last.Gerard BradyH-Index: 22
view all 17 authors...
Introduction: Tumor genomes can be reconstructed from the molecular information obtained from circulating cell-free DNA (cfDNA) and circulating tumor cells (CTCs) obtained from the peripheral blood of patients with cancer. The analysis of cfDNA and CTCs is a minimally invasive approach and represents a powerful research tool, with potential as a companion diagnostic for both patient stratification and monitoring. Here, we use cfDNA next-generation sequencing (NGS) analysis to assess and compare ...
#2Mahmood AyubH-Index: 5
Last.Matthew Krebs (University of Manchester)H-Index: 14
view all 9 authors...
Introduction Manchester Cancer Research Centre (MCRC) has established an MTB to facilitate precision medicine decision-making within the TARGET trial (Tumour chAracterisation to Guide Experimental Targeted Therapy). The MTB meets monthly to review clinical data and next generation sequencing (NGS) results from tumour tissue and circulating DNA (ctDNA) for patients being considered for early phase clinical trials. Initially the MTB relied on multiple paper reports. Here we present eTARGET, a digi...
#1Anthony Chiu (University of Manchester)H-Index: 1
#2Mahmood Ayub (University of Manchester)H-Index: 5
Last.Crispin J. Miller (University of Manchester)H-Index: 35
view all 5 authors...
123